{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:55:19Z","timestamp":1773467719704,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T00:00:00Z","timestamp":1682812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bullous pemphigoid (BP) is an autoimmune disease characterized by itchy erythema and tense blisters on the whole body. Recent reports have unveiled the pathogenic roles of eosinophils in BP (e.g., dermal\u2010epidermal separation, generation of pruritus). Thus, eosinophils are considered a therapeutic target. Benralizumab is an anti\u2010IL\u20105 receptor alpha (IL\u20105R\u03b1) monoclonal antibody (mAb) that is widely used to treat severe eosinophilic asthma. By affecting IL\u20105R\u03b1, benralizumab depletes eosinophils and basophils due to apoptosis through antibody\u2010dependent cell\u2010mediated cytotoxicity. The efficacies of benralizumab and other biologics, including bertilimumab (anti\u2010eotaxin\u20101 mAb) and mepolizumab (anti\u2010IL\u20105 mAb), were evaluated in several clinical trials. Also, reslizumab, an anti\u2010IL\u20105 mAb, was reported as a successful treatment option in a case of BP. We present a case of severe asthma treated with benralizumab at 8\u2010week intervals for 3\u2009years before BP developed. Histologically, subepidermal blisters without eosinophilic infiltration were observed. Methylprednisolone pulse therapy followed by 40\u2009mg\/day (1\u2009mg\/kg\/day) of oral prednisolone (PSL) was initiated, but the skin lesions worsened. Additional intravenous immunoglobulin and oral azathioprine enabled the oral PSL to be tapered. The benralizumab was discontinued after the onset of BP because the asthma did not worsen. To the best of our knowledge, there have been no reports of BP developing during anti\u2010eosinophil therapy. BP may occur paradoxically via various pathways during treatment with drugs that are typically effective against BP.<\/jats:p>","DOI":"10.1111\/1346-8138.16811","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T06:22:10Z","timestamp":1682922130000},"page":"1199-1202","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9533-1766","authenticated-orcid":false,"given":"Arisa","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Dermatology KKR Sapporo Medical Center  Sapporo Japan"},{"name":"Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido University  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Department of Dermatology KKR Sapporo Medical Center  Sapporo Japan"},{"name":"Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido University  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Fuke","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine KKR Sapporo Medical Center  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido University  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3489-5418","authenticated-orcid":false,"given":"Hideyuki","family":"Ujiie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido University  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00201"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.04.040"},{"key":"e_1_2_5_5_1","unstructured":"ClinicalTrials.gov[internet].National Library of Medicine (US). Available from:https:\/\/clinicaltrials.gov"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.020"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01238"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16679"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1992.tb03224.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117196"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.17.4.2877"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13950"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00619-1"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2022.08.004"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.622"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:52:13Z","timestamp":1694699533000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,30]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/1346-8138.16811"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16811","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,30]]},"assertion":[{"value":"2023-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}